![Patrick M. Schlievert](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrick M. Schlievert
Fondateur chez Hennepin Life Sciences LLC
Postes actifs de Patrick M. Schlievert
Sociétés | Poste | Début | Fin |
---|---|---|---|
Hennepin Life Sciences LLC
![]() Hennepin Life Sciences LLC Pharmaceuticals: MajorHealth Technology Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN. | Directeur/Membre du Conseil | 01/01/2009 | - |
Directeur Technique/Scientifique/R&D | 01/01/2009 | - | |
Fondateur | 01/01/2009 | - |
Historique de carrière de Patrick M. Schlievert
Anciens postes connus de Patrick M. Schlievert
Sociétés | Poste | Début | Fin |
---|---|---|---|
ImmuVen, Inc.
![]() ImmuVen, Inc. Drugstore ChainsRetail Trade ImmuVen, Inc. develops drugs to treat viral diseases and cancer. The firm develops biotherapeutics to treat cancer, infectious disease, and autoimmune disorders. It’s platform allows rapid selection and optimization of T cell receptors with high affinity to targets in cancer, infections, and autoimmune pathways. The company was founded by David Kranz and Patrick M Schlievert in November 2008 and is headquartered in Champaign, IL. | Fondateur | 01/11/2008 | - |
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
Founder | 2 |
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
Retail Trade | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
ImmuVen, Inc.
![]() ImmuVen, Inc. Drugstore ChainsRetail Trade ImmuVen, Inc. develops drugs to treat viral diseases and cancer. The firm develops biotherapeutics to treat cancer, infectious disease, and autoimmune disorders. It’s platform allows rapid selection and optimization of T cell receptors with high affinity to targets in cancer, infections, and autoimmune pathways. The company was founded by David Kranz and Patrick M Schlievert in November 2008 and is headquartered in Champaign, IL. | Retail Trade |
Hennepin Life Sciences LLC
![]() Hennepin Life Sciences LLC Pharmaceuticals: MajorHealth Technology Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN. | Health Technology |
- Bourse
- Insiders
- Patrick M. Schlievert
- Expérience